{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T21:54:32Z","timestamp":1788990872708,"version":"build-2803163510"},"reference-count":86,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Liver Disease"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.cld.2022.01.012","type":"journal-article","created":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T07:28:50Z","timestamp":1648798130000},"page":"291-312","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["The Use of Hepatitis C Virus\u2013Positive Organs in Hepatitis C Virus\u2013Negative Recipients"],"prefix":"10.1016","volume":"26","author":[{"given":"Christian","family":"Kuntzen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zohaib","family":"Bagha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 2","key":"10.1016\/j.cld.2022.01.012_bib1","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/ajt.16494","article-title":"OPTN\/SRTR 2019 annual data report: liver","volume":"21","author":"Kwong","year":"2021","journal-title":"Am J Transplant"},{"issue":"4","key":"10.1016\/j.cld.2022.01.012_bib2","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1056\/NEJMp1505074","article-title":"Transplanting hepatitis C\u2013positive kidneys","volume":"373","author":"Reese","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.cld.2022.01.012_bib3","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1111\/tri.13965","article-title":"Association between ethnicity and kidney transplant waitlist outcomes beyond estimated post-transplant survival score","volume":"34","author":"Homkrailas","year":"2021","journal-title":"Transpl Int"},{"issue":"5","key":"10.1016\/j.cld.2022.01.012_bib4","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.healun.2020.03.004","article-title":"Utilization of hepatitis C virus-infected organ donors in cardiothoracic transplantation: an ISHLT expert consensus statement","volume":"39","author":"Aslam","year":"2020","journal-title":"J\u00a0Heart Lung Transplant"},{"issue":"3","key":"10.1016\/j.cld.2022.01.012_bib5","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.jhep.2020.11.014","article-title":"Hepatitis C viraemic organs in solid organ transplantation","volume":"74","author":"Weinfurtner","year":"2021","journal-title":"J\u00a0Hepatol"},{"issue":"6","key":"10.1016\/j.cld.2022.01.012_bib6","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1002\/hep.30540","article-title":"Increasing utilization and excellent initial outcomes following liver transplant of hepatitis C virus (HCV)-viremic donors into HCV-negative recipients: outcomes following liver transplant of HCV-viremic donors","volume":"69","author":"Cotter","year":"2019","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.cld.2022.01.012_bib7","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jhep.2013.10.006","article-title":"Victory and defeat at Heraclea - treating hepatitis C infection following liver transplantation with telaprevir and boceprevir","volume":"60","author":"Charlton","year":"2014","journal-title":"J\u00a0Hepatol"},{"issue":"1","key":"10.1016\/j.cld.2022.01.012_bib8","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jhep.2013.08.018","article-title":"Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience","volume":"60","author":"Coilly","year":"2014","journal-title":"J\u00a0Hepatol"},{"issue":"2","key":"10.1016\/j.cld.2022.01.012_bib9","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/ajt.13976","article-title":"Changes in utilization and discard of hepatitis C-infected donor livers in the recent era","volume":"17","author":"Bowring","year":"2017","journal-title":"Am J Transpl"},{"issue":"5","key":"10.1016\/j.cld.2022.01.012_bib10","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/jvh.12148","article-title":"Meta-analysis of observational studies: hepatitis C and survival after renal transplant","volume":"21","author":"Fabrizi","year":"2014","journal-title":"J\u00a0Viral Hepat"},{"issue":"10","key":"10.1016\/j.cld.2022.01.012_bib11","doi-asserted-by":"crossref","first-page":"702","DOI":"10.7326\/M17-2451","article-title":"The drug overdose epidemic and deceased-donor transplantation in the United States: a national registry study","volume":"168","author":"Durand","year":"2018","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.cld.2022.01.012_bib12","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1111\/ajt.15162","article-title":"Liver transplantation for hepatitis C virus (HCV) non-viremic recipients with HCV viremic donors","volume":"19","author":"Kwong","year":"2019","journal-title":"Am J Transpl"},{"issue":"4","key":"10.1016\/j.cld.2022.01.012_bib13","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1002\/hep.29572","article-title":"The rise of the opioid epidemic and hepatitis C\u2013positive organs: a new era in liver transplantation","volume":"67","author":"Gonzalez","year":"2018","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.cld.2022.01.012_bib14","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1097\/TP.0000000000003382","article-title":"Liver transplantation of HCV-viremic donors into HCV-negative recipients in the United States: increasing frequency with profound geographic variation","volume":"105","author":"Cotter","year":"2021","journal-title":"Transplantation"},{"issue":"12","key":"10.1016\/j.cld.2022.01.012_bib15","doi-asserted-by":"crossref","first-page":"e2027551","DOI":"10.1001\/jamanetworkopen.2020.27551","article-title":"Donor characteristics and regional differences in the utilization of HCV-positive donors in liver transplantation","volume":"3","author":"Da","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"10","key":"10.1016\/j.cld.2022.01.012_bib16","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1002\/lt.20254","article-title":"Graft and patient survival after adult live donor liver transplantation compared to a matched cohort who received a deceased donor transplantation","volume":"10","author":"Thuluvath","year":"2004","journal-title":"Liver Transplant"},{"issue":"3","key":"10.1016\/j.cld.2022.01.012_bib17","doi-asserted-by":"crossref","first-page":"e13540","DOI":"10.1111\/tid.13540","article-title":"Hepatitis C-positive donor to negative recipient kidney transplantation: a real-world experience","volume":"23","author":"Jandovitz","year":"2021","journal-title":"Transpl Infect Dis"},{"issue":"1","key":"10.1016\/j.cld.2022.01.012_bib18","doi-asserted-by":"crossref","first-page":"e13204","DOI":"10.1111\/tid.13204","article-title":"Trends in utilization of deceased donor kidneys based on hepatitis C virus status and impact of public health service labeling on discard","volume":"22","author":"Ariyamuthu","year":"2020","journal-title":"Transpl Infect Dis"},{"issue":"5","key":"10.1016\/j.cld.2022.01.012_bib19","doi-asserted-by":"crossref","first-page":"e14281","DOI":"10.1111\/ctr.14281","article-title":"Transplantation of liver from hepatitis C-infected donors to hepatitis C RNA-negative recipients: histological and virologic outcome","volume":"35","author":"Nair","year":"2021","journal-title":"Clin Transplant"},{"issue":"8","key":"10.1016\/j.cld.2022.01.012_bib20","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.cgh.2017.04.041","article-title":"Biopsy specimens from allograft liver contain histologic features of hepatitis C virus infection after virus eradication","volume":"15","author":"Whitcomb","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.cld.2022.01.012_bib21","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1002\/lt.25741","article-title":"Use of hepatitis C nucleic acid test\u2013positive liver allografts in hepatitis C virus seronegative recipients","volume":"26","author":"Anwar","year":"2020","journal-title":"Liver Transplant"},{"issue":"2","key":"10.1016\/j.cld.2022.01.012_bib22","first-page":"113","article-title":"Hepatitis C and kidney disease: a narrative review","volume":"8","author":"Barsoum","year":"2017","journal-title":"J\u00a0Adv Res"},{"issue":"2","key":"10.1016\/j.cld.2022.01.012_bib23","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1002\/hep.31181","article-title":"Letter to the editor: safety first: favoring prophylactic\/preemptive over delayed treatment in D+\/R- transplants","volume":"72","author":"Terrault","year":"2020","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.cld.2022.01.012_bib24","doi-asserted-by":"crossref","first-page":"19","DOI":"10.4103\/0973-6247.126683","article-title":"Hepatitis C virus: screening, diagnosis, and interpretation of laboratory assays","volume":"8","author":"Gupta","year":"2014","journal-title":"Asian J Transfus Sci"},{"issue":"2","key":"10.1016\/j.cld.2022.01.012_bib25","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1046\/j.1365-2893.2001.00280.x","article-title":"Sensitivity and specificity of third-generation hepatitis C virus antibody detection assays: an analysis of the literature","volume":"8","author":"Colin","year":"2001","journal-title":"J\u00a0Viral Hepat"},{"issue":"10","key":"10.1016\/j.cld.2022.01.012_bib26","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1086\/508198","article-title":"Hepatitis C virus replicates in the liver of patients who have a sustained response to antiviral treatment","volume":"43","author":"Castillo","year":"2006","journal-title":"Clin Infect Dis"},{"issue":"10","key":"10.1016\/j.cld.2022.01.012_bib27","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1002\/jmv.21257","article-title":"Immune suppression leading to hepatitis C virus re-emergence after sustained virological response","volume":"80","author":"Lin","year":"2008","journal-title":"J\u00a0Med Virol"},{"issue":"6","key":"10.1016\/j.cld.2022.01.012_bib28","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S1470-2045(02)00773-8","article-title":"Reactivation of replication of hepatitis B and C viruses after immunosuppressive therapy: an unresolved issue","volume":"3","author":"Vento","year":"2002","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.cld.2022.01.012_bib29","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1002\/hep.29704","article-title":"Hepatitis C transmission from seropositive, nonviremic donors to non-hepatitis C liver transplant recipients","volume":"67","author":"Bari","year":"2018","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.cld.2022.01.012_bib30","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.jamcollsurg.2018.12.004","article-title":"Use of hepatitis C virus antibody-positive donor livers in hepatitis C nonviremic liver transplant recipients","volume":"228","author":"Luckett","year":"2019","journal-title":"J\u00a0Am Coll Surg"},{"issue":"6","key":"10.1016\/j.cld.2022.01.012_bib31","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/jvh.12534","article-title":"Treat chronic hepatitis C virus infection in decompensated cirrhosis - pre- or post-liver transplantation? the ironic conundrum in the era of effective and well-tolerated therapy","volume":"23","author":"Bunchorntavakul","year":"2016","journal-title":"J\u00a0Viral Hepat"},{"issue":"4","key":"10.1016\/j.cld.2022.01.012_bib32","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.jhep.2020.11.005","article-title":"Outcomes following liver transplantation from HCV-seropositive donors to HCV-seronegative recipients","volume":"74","author":"Aqel","year":"2021","journal-title":"J\u00a0Hepatol"},{"issue":"10","key":"10.1016\/j.cld.2022.01.012_bib33","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/S2468-1253(19)30240-7","article-title":"Pre-emptive pangenotypic direct acting antiviral therapy in donor HCV-positive to recipient HCV-negative heart transplantation: an open-label study","volume":"4","author":"Bethea","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.cld.2022.01.012_bib34","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/lt.25925","article-title":"Liver transplantation using hepatitis C virus-viremic donors into hepatitis C virus-aviremic recipients as standard of care","volume":"27","author":"Bohorquez","year":"2021","journal-title":"Liver Transpl"},{"issue":"1","key":"10.1016\/j.cld.2022.01.012_bib35","doi-asserted-by":"crossref","first-page":"e13761","DOI":"10.1111\/ctr.13761","article-title":"Liver, simultaneous liver-kidney, and kidney transplantation from hepatitis C-positive donors in hepatitis C-negative recipients: a single-center study","volume":"34","author":"Crismale","year":"2020","journal-title":"Clin Transplant"},{"issue":"8","key":"10.1016\/j.cld.2022.01.012_bib36","doi-asserted-by":"crossref","first-page":"e14386","DOI":"10.1111\/ctr.14386","article-title":"Outcomes of hepatitis C virus nucleic acid testing positive donors in aviremic recipients with delayed direct-acting antiviral initiation","volume":"35","author":"Hudson","year":"2021","journal-title":"Clin Transplant"},{"issue":"1","key":"10.1016\/j.cld.2022.01.012_bib37","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/hep.31011","article-title":"Hepatitis C virus NAT-positive solid organ allografts transplanted into hepatitis C virus-negative recipients: a real-world experience","volume":"72","author":"Kapila","year":"2020","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.cld.2022.01.012_bib38","doi-asserted-by":"crossref","first-page":"e13466","DOI":"10.1111\/tid.13466","article-title":"Utilization of hepatitis C viremic donors for liver transplant recipients without hepatitis C. A Veterans Transplant Center Report","volume":"23","author":"Said","year":"2021","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.cld.2022.01.012_bib39","doi-asserted-by":"crossref","first-page":"100318","DOI":"10.1016\/j.aohep.2021.100318","article-title":"Outcomes of hepatitis C virus seropositive donors to hepatitis C virus seronegative liver recipients: a large single center analysis","volume":"24","author":"Sobotka","year":"2021","journal-title":"Ann Hepatol"},{"issue":"5","key":"10.1016\/j.cld.2022.01.012_bib40","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1097\/TP.0000000000001704","article-title":"International Liver Transplantation Society consensus statement on hepatitis C management in liver transplant recipients","volume":"101","author":"Terrault","year":"2017","journal-title":"Transplantation"},{"issue":"6","key":"10.1016\/j.cld.2022.01.012_bib41","doi-asserted-by":"crossref","first-page":"e13194","DOI":"10.1111\/tid.13194","article-title":"Hepatitis C-positive donor liver transplantation for hepatitis C seronegative recipients","volume":"21","author":"Ting","year":"2019","journal-title":"Transpl Infect Dis"},{"issue":"6","key":"10.1016\/j.cld.2022.01.012_bib42","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1002\/hep.31551","article-title":"Prospective multicenter study of early antiviral therapy in liver and kidney transplant recipients of HCV-viremic donors","volume":"73","author":"Terrault","year":"2021","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.cld.2022.01.012_bib43","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1002\/hep.29918","article-title":"12 Weeks of a ribavirin-free sofosbuvir and nonstructural protein 5A inhibitor regimen is enough to treat recurrence of hepatitis C after liver transplantation","volume":"68","author":"Houssel-Debry","year":"2018","journal-title":"Hepatology"},{"issue":"11","key":"10.1016\/j.cld.2022.01.012_bib44","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1002\/lt.24614","article-title":"Sofosbuvir plus ledispasvir for recurrent hepatitis C in liver transplant recipients","volume":"22","author":"Kwok","year":"2016","journal-title":"Liver Transpl"},{"issue":"11","key":"10.1016\/j.cld.2022.01.012_bib45","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1681\/ASN.2020050686","article-title":"Multicenter study to transplant hepatitis C\u2013infected kidneys (MYTHIC): an open-label study of combined glecaprevir and pibrentasvir to treat recipients of transplanted kidneys from deceased donors with hepatitis C virus infection","volume":"31","author":"Sise","year":"2020","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.cld.2022.01.012_bib46","doi-asserted-by":"crossref","first-page":"137","DOI":"10.7326\/M20-1468","article-title":"Four-week direct-acting antiviral prophylaxis for kidney transplantation from hepatitis C-viremic donors to hepatitis C-negative recipients: an open-label nonrandomized study","volume":"174","author":"Durand","year":"2021","journal-title":"Ann Intern Med"},{"issue":"9","key":"10.1016\/j.cld.2022.01.012_bib47","doi-asserted-by":"crossref","first-page":"e13989","DOI":"10.1111\/ctr.13989","article-title":"Outcomes of the treatment with glecaprevir\/pibrentasvir following heart transplantation utilizing hepatitis C viremic donors","volume":"34","author":"Reyentovich","year":"2020","journal-title":"Clin Transplant"},{"issue":"2","key":"10.1016\/j.cld.2022.01.012_bib48","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1053\/j.semtcvs.2020.06.045","article-title":"Impact of early initiation of direct-acting antiviral therapy in thoracic organ transplantation from hepatitis C virus positive donors","volume":"33","author":"Smith","year":"2021","journal-title":"Semin Thorac Cardiovasc Surg"},{"issue":"17","key":"10.1016\/j.cld.2022.01.012_bib49","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1056\/NEJMoa1812406","article-title":"Heart and lung transplants from HCV-infected donors to uninfected recipients","volume":"380","author":"Woolley","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.cld.2022.01.012_bib50","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/ajt.15664","article-title":"Ultra-short duration direct acting antiviral prophylaxis to prevent virus transmission from hepatitis C viremic donors to hepatitis C negative kidney transplant recipients","volume":"20","author":"Gupta","year":"2020","journal-title":"Am J Transplant"},{"issue":"12","key":"10.1016\/j.cld.2022.01.012_bib51","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1097\/TP.0000000000001406","article-title":"Graft versus host disease after liver transplantation in adults: a case series, review of literature, and an approach to management","volume":"100","author":"Murali","year":"2016","journal-title":"Transplantation"},{"issue":"4","key":"10.1016\/j.cld.2022.01.012_bib52","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1002\/lt.21082","article-title":"Recipient and donor factors influence the incidence of graft-vs.-host disease in liver transplant patients","volume":"13","author":"Chan","year":"2007","journal-title":"Liver Transpl"},{"issue":"11","key":"10.1016\/j.cld.2022.01.012_bib53","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1002\/lt.22175","article-title":"Post\u2013liver transplant cholestatic hepatitis C: a systematic review of clinical and pathological findings and application of consensus criteria","volume":"16","author":"Narang","year":"2010","journal-title":"Liver Transplant"},{"issue":"1","key":"10.1016\/j.cld.2022.01.012_bib54","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/lt.23559","article-title":"Cholestatic hepatitis C following liver transplantation: an outcome-based histological definition, clinical predictors, and prognosis","volume":"19","author":"Verna","year":"2013","journal-title":"Liver Transpl"},{"issue":"1","key":"10.1016\/j.cld.2022.01.012_bib55","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/lt.500040102","article-title":"Cholestatic hepatitis after liver transplantation is associated with persistently high serum hepatitis C virus RNA levels","volume":"4","author":"Doughty","year":"1998","journal-title":"Liver Transpl Surg"},{"issue":"11","key":"10.1016\/j.cld.2022.01.012_bib56","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1053\/jlts.2003.50248","article-title":"The natural history and outcome of liver transplantation in hepatitis C virus-infected recipients","volume":"9","author":"Gane","year":"2003","journal-title":"Liver Transplant"},{"issue":"4","key":"10.1016\/j.cld.2022.01.012_bib57","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/j.1872-034X.2011.00781.x","article-title":"Clinical characterization of patients developing histologically-proven fibrosing cholestatic hepatitis C post-liver transplantation","volume":"41","author":"Satapathy","year":"2011","journal-title":"Hepatol Res"},{"issue":"5","key":"10.1016\/j.cld.2022.01.012_bib58","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1002\/hep.510230505","article-title":"Severe recurrent cholestatic hepatitis C following orthotopic liver transplantation","volume":"23","author":"Schluger","year":"1996","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.cld.2022.01.012_bib59","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1002\/hep.510260638","article-title":"Histological and clinical outcome after liver transplantation for hepatitis C","volume":"26","author":"Shuhart","year":"1997","journal-title":"Hepatology"},{"issue":"11","key":"10.1016\/j.cld.2022.01.012_bib60","doi-asserted-by":"crossref","first-page":"3046","DOI":"10.1111\/ajt.15530","article-title":"Transplantation of kidneys from hepatitis C-infected donors to hepatitis C-negative recipients: single center experience","volume":"19","author":"Molnar","year":"2019","journal-title":"Am J Transpl"},{"issue":"4","key":"10.1016\/j.cld.2022.01.012_bib61","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.cgh.2016.07.035","article-title":"Acute rejection increases risk of graft failure and death in recent liver transplant recipients","volume":"15","author":"Levitsky","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.cld.2022.01.012_bib62","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/lt.500010104","article-title":"Acute cellular rejection after liver transplantation: variability, morbidity, and mortality","volume":"1","author":"Fisher","year":"1995","journal-title":"Liver Transpl Surg"},{"issue":"4","key":"10.1016\/j.cld.2022.01.012_bib63","doi-asserted-by":"crossref","first-page":"e13833","DOI":"10.1111\/ctr.13833","article-title":"Transplantation of viral-positive hepatitis C-positive kidneys into uninfected recipients offers an opportunity to increase organ access","volume":"34","author":"Graham","year":"2020","journal-title":"Clin Transplant"},{"issue":"3","key":"10.1016\/j.cld.2022.01.012_bib64","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1111\/ajt.15152","article-title":"Transplantation of HCV-infected organs into uninfected recipients: advance with caution","volume":"19","author":"Wadei","year":"2019","journal-title":"Am J Transpl"},{"issue":"5","key":"10.1016\/j.cld.2022.01.012_bib65","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1097\/TP.0000000000001410","article-title":"Use of HCV+ donors does not affect HCV clearance with directly acting antiviral therapy but shortens the wait time to kidney transplantation","volume":"101","author":"Sawinski","year":"2017","journal-title":"Transplantation"},{"issue":"10","key":"10.1016\/j.cld.2022.01.012_bib66","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1007\/s40262-019-00774-0","article-title":"Viral hepatitis C therapy: pharmacokinetic and pharmacodynamic considerations: a 2019 update","volume":"58","author":"Smolders","year":"2019","journal-title":"Clin Pharm"},{"issue":"5","key":"10.1016\/j.cld.2022.01.012_bib69","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.jhep.2020.08.018","article-title":"EASL recommendations on treatment of hepatitis C: final update of the series(\u2606)","volume":"73","year":"2020","journal-title":"J\u00a0Hepatol"},{"issue":"1","key":"10.1016\/j.cld.2022.01.012_bib70","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1034\/j.1399-0012.2000.140101.x","article-title":"Central nervous system complications in liver transplant recipients--incidence, timing, and long-term follow-up","volume":"14","author":"Bronster","year":"2000","journal-title":"Clin Transplant"},{"issue":"4","key":"10.1016\/j.cld.2022.01.012_bib71","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1007\/s11940-012-0180-y","article-title":"Seizure treatment in transplant patients","volume":"14","author":"Shepard","year":"2012","journal-title":"Curr Treat Options Neurol"},{"issue":"16","key":"10.1016\/j.cld.2022.01.012_bib72","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1161\/CIRCULATIONAHA.114.009278","article-title":"Prevalence and prediction of coronary artery disease in patients with liver cirrhosis: a registry-based matched case-control study","volume":"130","author":"An","year":"2014","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.cld.2022.01.012_bib73","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jhep.2018.03.026","article-title":"EASL recommendations on treatment of hepatitis C 2018","volume":"69","year":"2018","journal-title":"J\u00a0Hepatol"},{"issue":"5","key":"10.1016\/j.cld.2022.01.012_bib74","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s40262-018-0710-1","article-title":"Cardiovascular risk management and hepatitis C: combining drugs","volume":"58","author":"Smolders","year":"2019","journal-title":"Clin Pharm"},{"issue":"6","key":"10.1016\/j.cld.2022.01.012_bib75","doi-asserted-by":"crossref","first-page":"105934","DOI":"10.1016\/j.ijantimicag.2020.105934","article-title":"Crushed application of sofosbuvir and velpatasvir in a patient with swallowing disorder","volume":"55","author":"van Seyen","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cld.2022.01.012_bib76","series-title":"5PSQ-029 Safe administration of sofosbuvir\/velpatasvir in a patient with percutaneous endoscopic gastrostomy","author":"C\u00e1ceres-Velasco","year":"2020"},{"issue":"5","key":"10.1016\/j.cld.2022.01.012_bib77","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1111\/jcpt.12713","article-title":"Successful treatment of chronic hepatitis C infection with crushed elbasvir\/grazoprevir administered via a percutaneous endoscopic gastrostomy tube","volume":"43","author":"Yap","year":"2018","journal-title":"J\u00a0Clin Pharm Ther"},{"issue":"5","key":"10.1016\/j.cld.2022.01.012_bib78","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1177\/0897190017731245","article-title":"Treatment of chronic hepatitis C virus infection with crushed ledipasvir\/sofosbuvir administered via a percutaneous endoscopic gastrostomy tube","volume":"31","author":"Jindracek","year":"2018","journal-title":"J\u00a0Pharm Pract"},{"issue":"6","key":"10.1016\/j.cld.2022.01.012_bib79","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1016\/j.xphs.2018.02.015","article-title":"A\u00a0phase 1 study to evaluate the effect of crushing, cutting into half, or grinding of glecaprevir\/pibrentasvir tablets on exposures in healthy subjects","volume":"107","author":"Oberoi","year":"2018","journal-title":"J\u00a0Pharm Sci"},{"issue":"4","key":"10.1016\/j.cld.2022.01.012_bib80","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.cgh.2018.08.042","article-title":"Cost effectiveness of transplanting HCV-infected livers into uninfected recipients with preemptive antiviral therapy","volume":"17","author":"Bethea","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10","key":"10.1016\/j.cld.2022.01.012_bib81","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1111\/ajt.14929","article-title":"Cost-effectiveness of using kidneys from hepatitis C nucleic acid test-positive donors for transplantation in hepatitis C-negative recipients","volume":"18","author":"Kadatz","year":"2018","journal-title":"Am J Transplant"},{"issue":"24","key":"10.1016\/j.cld.2022.01.012_bib82","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1056\/NEJMc1705221","article-title":"Trial of transplantation of HCV-infected kidneys into uninfected recipients","volume":"376","author":"Goldberg","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.cld.2022.01.012_bib83","doi-asserted-by":"crossref","first-page":"273","DOI":"10.7326\/M18-0749","article-title":"Twelve-month outcomes after transplant of hepatitis C\u2013infected kidneys into uninfected recipients: a single-group trial","volume":"169","author":"Reese","year":"2018","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.cld.2022.01.012_bib84","doi-asserted-by":"crossref","first-page":"e13146","DOI":"10.1111\/tid.13146","article-title":"Successful early sofosbuvir-based antiviral treatment after transplantation of kidneys from HCV-viremic donors into HCV-negative recipients","volume":"21","author":"Friebus-Kardash","year":"2019","journal-title":"Transpl Infect Dis"},{"issue":"8","key":"10.1016\/j.cld.2022.01.012_bib85","doi-asserted-by":"crossref","first-page":"533","DOI":"10.7326\/M17-2871","article-title":"Direct-acting antiviral prophylaxis in kidney transplantation from hepatitis C virus\u2013infected donors to noninfected recipients: an open-label nonrandomized trial","volume":"168","author":"Durand","year":"2018","journal-title":"Ann Intern Med"},{"issue":"7","key":"10.1016\/j.cld.2022.01.012_bib86","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1111\/tri.13410","article-title":"Renal transplantation from seropositive hepatitis C virus donors to seronegative recipients in Spain: a prospective study","volume":"32","author":"Franco","year":"2019","journal-title":"Transpl Int"},{"issue":"1","key":"10.1016\/j.cld.2022.01.012_bib87","first-page":"89","article-title":"Pan-genotype pre-exposure prophylaxis (PrEP) allows transplantation of HCV-positive donor kidneys to negative transplant recipients","volume":"10","author":"Duerr","year":"2021","journal-title":"J\u00a0Clin Med"},{"issue":"6","key":"10.1016\/j.cld.2022.01.012_bib88","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1111\/ajt.15768","article-title":"Immediate administration of antiviral therapy after transplantation of hepatitis C-infected livers into uninfected recipients: implications for therapeutic planning","volume":"20","author":"Bethea","year":"2020","journal-title":"Am J Transplant"}],"container-title":["Clinics in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326122000125?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326122000125?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T17:58:44Z","timestamp":1761069524000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1089326122000125"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":86,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S1089326122000125"],"URL":"https:\/\/doi.org\/10.1016\/j.cld.2022.01.012","relation":{},"ISSN":["1089-3261"],"issn-type":[{"value":"1089-3261","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Use of Hepatitis C Virus\u2013Positive Organs in Hepatitis C Virus\u2013Negative Recipients","name":"articletitle","label":"Article Title"},{"value":"Clinics in Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cld.2022.01.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}